Abstract
The Use of Nonhuman Primate Models in HIV Vaccine Development
Highlights
Cecilia Morgan*B, Marta MarthasB, Christopher MillerB, Ann Duerr, Cecilia Cheng-Mayer, Ronald Desrosiers, Jorge Flores, Nancy Haigwood, Shiu-Lok Hu, R
The primary expected outcome for T cell vaccines is the control of viral replication after experimental challenge with simian immunodeficiency virus (SIV) in nonhuman primate (NHP) or natural infection with HIV-1 in humans
Progress toward developing an AIDS vaccine has been hampered by the lack of clarity about what host immune responses are required to prevent HIV-1 transmission or protect against disease progression
Summary
Cecilia Morgan*B, Marta MarthasB, Christopher MillerB, Ann Duerr, Cecilia Cheng-Mayer, Ronald Desrosiers, Jorge Flores, Nancy Haigwood, Shiu-Lok Hu, R. The most rigorous approach to judging the potential efficacy of HIV-1 vaccine candidates in NHP models is to determine if prototype vaccine candidates can protect the animals from the uncontrolled replication of a virulent challenge virus that recapitulates the pathogenic effects of HIV-1 in humans.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
